Here are the 424B prospectus supplements from Passage Bio, Inc. (PASG) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow PASG and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PASG filings page.
Passage Bio, Inc. and Remix Therapeutics, Inc. have agreed to a two-step merger: Remix would first become a wholly owned Passage Bio subsidiary, then merge into another wholly owned subsidiary; Passage Bio would be renamed Remix Therapeutics, Inc. Remix shares outside the concurrent financing would convert at an assumed 0.1727 exchange ratio, while shares issued in the financing use an assumed 0.1728 ratio; both ratios are subject to adjustments.
Remix’s concurrent financing combines approximately $70.0 million from common-stock and pre-funded-warrant sales with approximately $30.0 million of convertible notes, for expected aggregate gross proceeds of approximately $100.0 million. Closing requires Passage Bio stockholder approval of the stock issuance, reverse split and charter proposals, plus at least $99,929,000 in concurrent-financing proceeds at or substantially simultaneously with closing. The reverse split proposal ranges from 1-for-2 to 1-for-10. On stated assumptions, fully diluted post-closing ownership is projected at approximately 65% for Remix’s pre-merger holders, 6% for Passage Bio’s pre-merger holders and 29% for financing investors. The special meeting is scheduled for November 5, 2026, unless postponed or adjourned.